Windlas Biotech Ltd — earnings calls

Windlas Biotech reported FY26 revenue of INR904 crores, up 19% year-on-year, with Q4 FY26 revenue at INR238 crores, up 18% year-on-year, marking 13 consecutive quarters of record revenue. Management attributed growth to the CDMO vertical, which grew 20% year-on-year, while the Trade Generics and Institutional vertical faced softness from the exit of codeine-based cough syrups. The company also reported completion of a buyback, a proposed dividend, and progress on Plant 6, which reached mechanical completion and is expected to commercialize in H1 FY27.